Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 24


Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Atigadda VR, Xia G, Deshpande A, Wu L, Kedishvili N, Smith CD, Krontiras H, Bland KI, Grubbs CJ, Brouillette WJ, Muccio DD.

J Med Chem. 2015 Oct 8;58(19):7763-74. doi: 10.1021/acs.jmedchem.5b00829. Epub 2015 Sep 22.


Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2015 Jul;14(7):1559-69. doi: 10.1158/1535-7163.MCT-14-1103. Epub 2015 May 5.


Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.

Atigadda VR, Xia G, Desphande A, Boerma LJ, Lobo-Ruppert S, Grubbs CJ, Smith CD, Brouillette WJ, Muccio DD.

J Med Chem. 2014 Jun 26;57(12):5370-80. doi: 10.1021/jm5004792. Epub 2014 Jun 5.


Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Desphande A, Xia G, Boerma LJ, Vines KK, Atigadda VR, Lobo-Ruppert S, Grubbs CJ, Moeinpour FL, Smith CD, Christov K, Brouillette WJ, Muccio DD.

Bioorg Med Chem. 2014 Jan 1;22(1):178-85. doi: 10.1016/j.bmc.2013.11.039. Epub 2013 Dec 1.


Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.

Boerma LJ, Xia G, Qui C, Cox BD, Chalmers MJ, Smith CD, Lobo-Ruppert S, Griffin PR, Muccio DD, Renfrow MB.

J Biol Chem. 2014 Jan 10;289(2):814-26. doi: 10.1074/jbc.M113.476861. Epub 2013 Nov 1.


Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R.

Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404. Epub 2013 Jan 4.


The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.


The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425. Epub 2011 Dec 9.


The use of retinoids in ovarian cancer: a review of the literature.

Whitworth JM, Straughn JM Jr, Atigadda VR, Muccio DD, Buchsbaum DJ.

Int J Gynecol Cancer. 2012 Feb;22(2):191-8. doi: 10.1097/IGC.0b013e318236a2ec. Review.


A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline.

Jackson PL, Noerager BD, Jablonsky MJ, Hardison MT, Cox BD, Patterson JC, Dhanapal B, Blalock JE, Muccio DD.

Eur J Pharmacol. 2011 Oct 15;668(3):435-42. doi: 10.1016/j.ejphar.2011.02.045. Epub 2011 Mar 31.


A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.

Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE.

Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70. doi: 10.1158/1940-6207.CAPR-10-0149.


Structure, energetics, and dynamics of binding coactivator peptide to the human retinoid X receptor α ligand binding domain complex with 9-cis-retinoic acid.

Xia G, Boerma LJ, Cox BD, Qiu C, Kang S, Smith CD, Renfrow MB, Muccio DD.

Biochemistry. 2011 Jan 11;50(1):93-105. Epub 2010 Dec 8.


Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.

Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM.

Cancer Biol Ther. 2009 Feb;8(3):289-98. Epub 2009 Feb 21.


The Novel Retinoid, 9cUAB30, Inhibits Telomerase and Induces Apoptosis in HL60 Cells.

Love WK, Deangelis JT, Berletch JB, Phipps SM, Andrews LG, Brouillette WJ, Muccio DD, Tollefsbol TO.

Transl Oncol. 2008 Sep;1(3):148-52.


In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid.

Gorman GS, Coward L, Kerstner-Wood C, Cork L, Kapetanovic IM, Brouillette WJ, Muccio DD.

Drug Metab Dispos. 2007 Jul;35(7):1157-64. Epub 2007 Apr 19.


Conformation of 3'CMP bound to RNase A using TrNOESY.

Lee YC, Jackson PL, Jablonsky MJ, Muccio DD.

Arch Biochem Biophys. 2007 Jul 1;463(1):37-46. Epub 2007 Mar 19.


Expression of crustacean (Callinectes sapidus) molt-inhibiting hormone in Escherichia coli: characterization of the recombinant peptide and assessment of its effects on cellular signaling pathways in Y-organs.

Nakatsuji T, Han DW, Jablonsky MJ, Harville SR, Muccio DD, Watson RD.

Mol Cell Endocrinol. 2006 Jul 11;253(1-2):96-104. Epub 2006 Jun 21.


Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.

Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD.

Carcinogenesis. 2006 Jun;27(6):1232-9. Epub 2005 Dec 12.


Biochemical characterization and crystallization of recombinant 3-phosphoglycerate kinase of Plasmodium falciparum.

Pal B, Pybus B, Muccio DD, Chattopadhyay D.

Biochim Biophys Acta. 2004 Jun 1;1699(1-2):277-80.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk